Qfitlia (fitusiran) is the first therapy for both hemophilia A or B, with or without inhibitors, available in the United States.

Fitusiran is a small interference RNA therapeutic designed to prevent bleeds in patients with hemophilia A or B by lowering antithrombin.

The U.S. Food and Drug Administration has approved Sanofi's Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce ...

Unlike other hemophilia therapies, Qfitlia is indicated for both hemophilia A and B, and can be given in patients regardless ...

The findings showed that fitusiran lowers antithrombin levels to enhance thrombin generation and restore hemostasis in ...

Qfitlia contains fitusiran, which uses RNA interference (RNAi) to block the production of AT, providing effective treatment for hemophilia, even in patients with inhibitors. It is given as a shot ...

The FDA has approved fitusiran, now named Qfitlia, for routine prophylaxis in patients aged 12 and older with hemophilia A or ...

The U.S. Food and Drug Administration on Friday approved Sanofi SA’s (NASDAQ:SNY) Qfitlia (fitusiran), the first antithrombin ...

The FDA has recently approved two new prophylactic treatments for people with hemophilia who develop antibodies to clotting ...

Sanofi's Qfitlia gains FDA approval, offering fewer injections in hemophilia care. Check out my recommendation for SNY stock.

Fitusiran is an anti-thrombin-directed small interfering ribonucleic acid therapeutic that prevents bleeds in patients with hemophilia A or B by reducing antithrombin levels. The efficacy and ...